

12

EUROPEAN PATENT APPLICATION

21 Application number: 88302319.4

51 Int. Cl.⁵: **A61K 31/55**

22 Date of filing: 17.03.88

30 Priority: 23.03.87 US 29289

43 Date of publication of application:
05.10.88 Bulletin 88/40

54 Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

58 Date of deferred publication of the search report:
16.08.90 Bulletin 90/33


71 Applicant: **SMITHKLINE BECKMAN
CORPORATION**
One Franklin Plaza P O Box 7929
Philadelphia Pennsylvania 19103(US)

72 Inventor: **Bondinell, William Edward**
1512 Franklin Lane
Wayne Pennsylvania 19087(US)
Inventor: **Ormsbee III, Herbert Stowell**
652 Pugh Road
Wayne Pennsylvania 19087(US)

74 Representative: **Waters, David Martin, Dr. et al**
Smith Kline & French Laboratories Ltd.
Patent Department Mundells
Welwyn Garden City Hertfordshire AL7
1EY(GB)

54 **3-Benzazepine compounds for use in treating gastrointestinal motility disorders.**

57 The use of a compound of the formula (I) :



drogen or C₁-C₆ alkyl; and n is 0, 1 or 2; provided R² is not hydrogen when R³ is S-phenyl in the 6-position and provided that when R² is hydroxy in the 8-position and R¹ is C₁-C₆ alkyl, R³ may be halogen or CF₃ only if it is in the 6- or 9-position.

EP 0 285 287 A3

or a pharmaceutically acceptable acid addition salt thereof, in the manufacture of a medicament for the treatment of gastrointestinal motility disorders is described wherein R¹ is hydrogen, C₁-C₆ alkyl or C₃-C₅ alkenyl; R² is hydrogen, halogen, CF₃, C₁-C₆ alkyl or R⁴O; R³ is halogen, CF₃, C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, S-(C₁-C₆) alkyl, S-trifluoromethyl, NO₂, SO_n-phenyl where the phenyl is optionally substituted by hydroxy, C₁-C₆ alkoxy, halogen, CF₃, C₁-C₆ alkyl, SO_n(C₁-C₆) alkyl, SO_nCF₃, SO_n-phenyl or SO₂NR⁵R⁶; R⁴ is hydrogen, C₁-C₆ alkyl, or C₁-C₆alkanoyl; R⁵ and R⁶ are hy-



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
D,X	US-A-4 265 890 (K.G. HOLDEN) * Column 1, lines 8-59; claims 1,2,10-13 * ---	1-13	A 61 K 31/55 C 07 D 223/16
P,X	EP-A-0 216 247 (MERCK & CO. INC.) * Column 1, lines 10-23; claims 1,2 * ---	1-13	
P,X	EP-A-0 229 510 (SMITHKLINE BECKMAN) * Page 2, lines 1-38; page 4, line 44 - page 5, line 25; claims * ---	1-13	
X	CH-A- 498 123 (J.R. GEIGY AG) * The whole document *	10	
Y	---	1-9,11-13	
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 9, September 1983, American Chemical Society; R.M. DeMARINIS et al.: "6-Chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine: A potent and selective antagonist of alpha2-adrenoceptors" * The whole document * -----	1-13	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 23-05-1990	Examiner ORVIZ DIAZ P.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	